| Literature DB >> 35185356 |
Vrish Dhwaj Ashwlayan1, Chanchal Antlash1, Mohd Imran2, Syed Mohammed Basheeruddin Asdaq3, Mohammed Kanan Alshammari4, Marwa Alomani5, Eman Alzahrani5, Divya Sharma6, Ritu Tomar7, Mandeep Kumar Arora7.
Abstract
COVID-19 (coronavirus disease-2019) is a contagious illness that has been declared a global epidemic by the World Health Organization (WHO). The coronavirus causes diseases ranging in severity from the common cold to severe respiratory diseases and death. Coronavirus primarily affects blood pressure by attaching to the angiotensin converting enzyme 2 (ACE 2) receptor. This virus has an impact on multiple organ systems, including the central nervous system, immune system, cardiovascular system, peripheral nervous system, gastrointestinal tract, endocrine system, urinary system, skin, and pregnancy. For the prevention of COVID-19, various vaccines such as viral-like particle vaccines, entire inactivated virus vaccines, viral vector vaccines, live attenuated virus vaccines, subunit vaccines, RNA vaccines, and DNA vaccines are now available. Some of the COVID-19 vaccines are reported to cause a variety of adverse effects that range from mild to severe in nature. SARS-CoV-2 replication is controlled by the RNA-Dependent RNA-Polymerase enzyme (RdRp). The availability of FDA-approved anti-RdRp drugs (Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir) as potent drugs against SARS-CoV-2 that tightly bind to its RdRp may aid in the treatment of patients and reduce the risk of the mysterious new form of COVID-19 viral infection. RdRp inhibitors, such as remdesivir (an anti-Ebola virus experimental drug) and favipiravir (an anti-influenza drug), inhibit RdRp and thus slow the progression of COVID-19 and associated clinical symptoms, as well as significantly shorten recovery time. Molnupiravir, an orally active RdRp inhibitor and noval broad spectrum antiviral agent, is an isopropyl pro-drug of EIDD-1931 for emergency use. Galidesivir's in vitro and in vivo activities are limited to RNA of human public health concern. Top seeds for antiviral treatments with high potential to combat the SARS-CoV-2 strain include guanosine derivatives (IDX-184), setrobuvir, and YAK. The goal of this review is to compile scattered information on available COVID-19 vaccines and other treatments for protecting the human body from their harmful effects and to provide options for making better choices in a timely manner.Entities:
Keywords: Biological impact; COVID-19; Global health; SARS-CoV; Transmission; Vaccine
Year: 2022 PMID: 35185356 PMCID: PMC8837491 DOI: 10.1016/j.sjbs.2022.02.010
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.052
Vaccines available for COVID-19.
| Covishield (Serum Institute of India, Pune with Oxford, and AstraZeneca) | Ad26.COV2. S (Janssen Pharmaceuticals) | Covishield vaccine (ChAdOx1 nCoV 19), marked as AZD1222, is a viral vector vaccine manufactured at Oxford University/AstraZeneca with Serum Institute of India (SII) giving a platform to generate a vaccine in India |
| Covaxin (Bharat Biotech, Hyderabad with ICMR) | Novavax | Covaxin (BBV152) is an entire virion inactivated SARS-CoV-2 vaccine and is the earliest vaccine which has been natively developed. Covaxin has been prepared by Bharat Biotech as a team with the Indian Council of Medical Research |
| Moderna | ZF2001 | The Moderna vaccine is a lipid nanoparticle enclosed mRNA-based vaccine that encodes the prefusion balanced out full length spike protein of the SARS-CoV-2. This is interesting that m-RNA platform has been utilized and there have been numerous hypotheses regarding this vaccine |
| Pfizer + BioNTech | Zorecimeran (CVnCoV) | Pfizer and BioNTech have developed BNT162b2, a lipid-soluble nano particle-based mRNA vaccine. The vaccine comprises of perfusion conformity of the full-length S gene |
| Zydus Cadila (Zydus Biotech, Ahmedabad) | CoVLP | The Beijing Institute of Biological Products developed the inactivated BBIBP CorV vaccine. Deactivated with β-propyl lactone, this vaccine, prompted significant titres of counteracting antibodies in mice and Rhesus monkeys |
| Sputnik-V | IIBR-100 | The Gamaleya Research Institute, Russia prepared its human adenovirus (Ad) vector-based vaccine, the Sputnik-V, which has a full-length S-gene. The unconventional property of this vaccine is that it uses 2 adenovirus (Ad) vectors-Ad5 and Ad-26 |
| CanSinoBIO (Beijing Institute of Biotechnology) | GRAd-COV2 | CanSino Biological’s vaccine candidate for Ebola into phase 2 trials after preliminary safety data showed efficacy against Covid-19 |
| CoronaVac (Sinovac Life Sciences, China) | INO-4800 | A multivalent deactivated vaccine that attacks on SARS-CoV-2 strains spreading in various areas, CoronaVac, was prepared by SinoVac Life Sciences, Beijing, China. β-propyl lactone was used to deactivate the viral seed which was cultured in Vero cells |
| EpiVacCorona (Vektor State Research Center of Virology and Biotechnology in Russia) | The peptide-based COVID-19 preventive vaccine is the second to be licensed for use in Russia | |
| Zydus cadila vaccine | ZYCoV-D is another natively prepared plasmid DNA third-era vaccine where DNA, the functional segment of virus is introduced into the plasmid that is non-replicating and non-incorporating. This recombinant plasmid is then accessible in vaccine form which develops antigen-antibody reaction and cell mediated immunity ( |
Other antiviral treatment for Covid-19.
| Remdesivir | Solution/Powder | Intravenous/200 mg loading dose, followed by 100 mg once daily for 5–10 days for adults | COVID-19 patients of ≥12 years requiring hospitalization | It reduces the requirement of high level of respiratory (oxygen) support. There is no evidence of resistance development upon its long term exposure | Signs of an allergic reaction: |
| Favipiravir | Film-coated tablet | Oral/1800 mg/dose twice a day on the first day; followed by 800 mg/dose twice a day for 7–10 days for adults | COVID-19 | Favipiravir provides multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy | It has poor pharmacokinetic profile |
| Molnupiravir | 800 mg PO q12hr for 5 days | Emergency use authorization issued for treatment of mild-to-moderate (COVID-19) in adults testing positive for severe acute respiratory syndrome (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19 (hospitalization or death) after COVID-19 | It has quick onset of action, a wide therapeutic window, excellent tolerance with a good safety profile, fewer adverse reactions and good tolerability due to its better bioavailability; quick clearance of SARs-COV-2; & no accumulative toxicity | Emergency use | |
| Galidesivir | Galidesivir an adenosine nucleoside analog phase I clinical trials, including against SARS COV-2 |
Benefits and drawbacks of different Covid vaccines.
| Entire inactivated virus vaccine | Powerful immune response; Safer than live attenuated virus | Potential epitope modification by deactivation process |
| Live attenuated virus vaccine | Stronger immune response; Local antigen conservation; Copying natural infection | Threat of persisting virulence, especially for immunocompromised persons |
| Viral vector vaccine | Stronger immune response; Local antigen preservation; Copying natural infection | More intricated manufacturing procedure; Threat of genomic unification; Pre-existing immunity to the vector diminished the response |
| Subunit vaccine | Safe and well-tolerated | Reduce immunogenicity: To improve immunogenicity, an adjuvant or conjugate is required to reduce immunogenicity |
| Vaccine with viral-like particles | Safe and well-tolerated; copying native virus conformation | Reduce immunogenicity; More intricated development process |
| DNA vaccine | Safe and very much endured; Stable under room temperature; Extremely versatile to new microbe; Native antigen expression | Reduce immunogenicity; Difficult introduction route; Threat of genomic integration |
| RNA vaccine | Safe and very much endured; Extremely versatile to new microorganism; Native antigen expression | Reduce immunogenicity; Need of low temperature storage and shipping; Potential threat of RNA-incited interferon reaction ( |
| Redness, Inflammation, Pain at injection site | ||
| Pyrexia, Headache, Chills, Vomiting, Loose motions, New or worsening joint pain, Lymphadenopathy, Bell’s palsy | ||
| Appendicitis, Myocardial infarction, Cerebrovascular accident, Shoulder injury, Lymphadenopathy on contralateral side | ||
Impact of Covid-19 and its vaccines on human health.
| SARS-CoV-2 mostly attacks on alveolar epithelial cells, bringing about respiratory side effects. According to research, 4 out of 5 sufferers which have myocardial injury were hospitalized and bedded into the ICU, which manifests the critical condition of the myocardial injury in sick persons who have coronavirus disease. The sick person also had remarkably elevated blood pressure | |
| Local immune reactions are activated by the demolition of cells in the lungs and SARS-CoV-2 disease, enlisting macrophages and monocytes that react to the infection, liberate cytokines and stimulate adaptive T and B cell immune reactions. Local immune reactions are activated by the demolition of cells in the lungs and SARS-CoV-2 disease, enlisting macrophages and monocytes that react to the infection, liberate cytokines and stimulate adaptive T and B cell immune reactions. In many people, selected cells clean the virus from the lungs, the immune reactions subside, and sick person recuperate. In certain sufferers, a defected immune reaction happens, this reduces the lung’s ability to exchange gases, lower blood oxygen levels and create problems in respiration. The lungs additionally turn out to be more defenceless against another infection | |
| Currently procurable proof recommends that the SARS-CoV-2 infection can penetrate the brain and disrupt the BBB. The virus can likewise penetrate the cerebrum | |
| The most recurrent neurological symptoms of coronavirus disease include a total or incomplete loss of taste sensation and smell sensation. COVID-19 influences smell sensation more seriously in comparison to ageusia. The ordinary early symptoms of coronavirus infection are tiredness and muscle pain or myalgia | |
| Pregnant ladies go through physiological changes, which promote altered immune system. As per an investigation, pregnancy itself doesn't exacerbate the manifestations experienced, nor the detecting on a computerized tomography of coronavirus disease allied pneumonia. Three investigations have found no maternal difficulties, for example, postnatal coronavirus infection and premature labour. Notwithstanding, different investigations have announced both foetal and maternal difficulties such as premature birth, foetal misery, respiratory misery, and premature rupture of membranes. Baud et al. informed about a spontaneous abortion in a lady with coronavirus disease throughout the second trimester of pregnancy, which looked to be connected to SARS-CoV-2 placental disease | |
| As per RCOG, there is not sufficient information at present to give a relationship between the Coronavirus disease and chance of spontaneous abortion or that the infection has teratogenicity. Premature birth is because of iatrogenic aetiology or different factors, further research is needed for a decisive result | |
| Numerous investigations reported symptomless infants, delivered from COVID-19 infected mothers. An investigation by Zhu et al. has announced new-borns COVID-19 manifestations to incorporate dyspnea, pyrexia, and gastrointestinal manifestations like vomiting and abdominal distension | |
| While most Coronavirus disease have respiratory sickness, a few individuals described gastrointestinal manifestations like loose bowels, spewing, and abdominal discomfort throughout the time of the infection | |
| Patients with coronavirus disease could have liver damage with increased enzymes detected in blood tests. The portion of liver damage was additionally higher in patients which have serious coronavirus disease | |
| The skin problems in the coronavirus disease were at the beginning because of the hyperhydration impact of PPE, epidermal barrier breakdown, abrasion, and contact responses, all of them may exasperate an earlier skin sickness. Various skin changes have been reported like skin redness, papules, maceration, and scaling by the wearing of personal protective equipment (PPE). Clinical symptoms contain itching, stinging, and burning | |
| Various endocrine glands have ACE2, to be specific thyroid, pancreas, ovary, testis, pituitary and adrenal glands. Despite the fact that one could anticipate endocrine repercussions because of reaction of SARS-CoV-2 with ACE2 present on these glands, there is no clinical or pre-clinical information till now. There is damage in exocrine pancreas showed as raised serum amylase as well as lipase in seventeen percent and one to two percent of sufferers with serious and non-serious COVID-19 patients, respectively | |
| In SARS-CoV-2 infection, just as in different contagious sicknesses, for example, flu, varicella, dengue, HIV, MERS-CoV and SARS-CoV, hematological changes can happen. The most widely recognized hematological detection contains lymphocytopenia, neutrophilia, eosinopenia, less frequently thrombocytosis and mild thrombocytopenia | |
| Coronavirus disease can produce acute kidney infection and is a distinct threat part for death rate. It additionally affects sufferers having chronic kidney disease, renal relocation, and chronic substitution treatments | |
| The vaccines for COVID-19 have powerful immune response, safe and well-tolerated. But these vaccines have some drawbacks like threat of persisting virulence, especially for immunocompromised persons, reduce immunogenicity and threat of genomic unification; Pre-existing immunity to the vector diminished the response. |